Valentine Capital Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Valentine Capital Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	$257K	Sell	1,350 -225	-14%	-$39.3K	0.29%	66
2015 Q3	$246K	Sell	1,575 -540	-26%	-$98.5K	0.22%	76
2015 Q2	$382K	Sell	2,115 -1,970	-48%	-$340K	0.26%	69
2015 Q1	$708K	Sell	4,085 -1,340	-25%	-$243K	0.21%	83
2014 Q4	$1M	Buy	5,425 +90	+2%	+$16.7K	0.24%	83
2014 Q3	$885K	Buy	+5,335	New	+$876K	0.34%	42
2014 Q2	–	Sell	-54,978	Closed	-$8.36M	–	131
2014 Q1	$8.36M	Buy	54,978 +34,740	+172%	+$5.52M	1.74%	13
2013 Q4	$2.69M	Buy	20,238 +75	+0.4%	+$9K	0.58%	65
2013 Q3	$2.34M	Buy	20,163 +1,081	+6%	+$119K	0.61%	60
2013 Q2	$1.76M	Buy	+19,082	New	+$1.84M	0.55%	61

Other funds holding ALXN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Valentine Capital Asset Management's ALXN Position: Q4 2015 in Review

Valentine Capital Asset Management reduced its Alexion Pharmaceuticals (ALXN) stake by 14% in Q4 2015, selling an estimated $39.3K and leaving 1,350 shares worth $257K. The position accounts for 0.29% of the portfolio, ranked #66.

Valentine Capital Asset Management first reported a position in ALXN in Q2 2013 and has held it in 10 quarters since. The position peaked at $8.36M in Q1 2014. 548 funds tracked by Wall St. Rank hold ALXN as of Q4 2015.

Valentine Capital Asset Management held 1,350 shares of Alexion Pharmaceuticals worth $257K as of Q4 2015.
Valentine Capital Asset Management sold 225 Alexion Pharmaceuticals shares in Q4 2015, an estimated $39.3K.
Alexion Pharmaceuticals made up 0.29% of Valentine Capital Asset Management's portfolio in Q4 2015, its #66 holding.
Valentine Capital Asset Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and has held it in 10 quarters since.
Valentine Capital Asset Management's Alexion Pharmaceuticals position peaked at $8.36M in Q1 2014.
548 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2015.

Based on Valentine Capital Asset Management's 13F filing for Q4 2015, filed 17 Feb 2016.